Volunteer Login Study Team Login

Print

Lay Description

Phase 2 multicenter study to be conducted in up to 50 qualified participating sites in the United States to assess the efficacy and safety of Reltecimod vs placebo in patients with abdominal sepsis-associated Stage 2/3 AKI.

Category

  • Heart, Vascular and Blood
  • Urinary Tract and Kidney
IRB Number
20180730HU
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
18 Years - 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Study Contact


Regulatory Point of Contact
Melissa Frei-Jones
(210) 567-7477
freijones@uthscsa.edu

Regulatory Point of Contact
Raquel Reyes
2105677469
reyesrf@uthscsa.edu

Local Recruitment Point of Contact
Raquel Reyes
2105677469
reyesrf@uthscsa.edu

Principal Investigator
Melissa Frei-Jones